Jump to content

Search the hub

Showing results for tags 'Adverse reaction'.


More search options

  • Search By Tags

    Start to type the tag you want to use, then select from the list.

  • Search By Author

Content Type


Forums

  • All
    • Commissioning, service provision and innovation in health and care
    • Coronavirus (COVID-19)
    • Culture
    • Digital health and care service provision
    • Improving patient safety
    • Investigations, risk management and legal issues
    • Leadership for patient safety
    • Organisations linked to patient safety (UK and beyond)
    • Patient engagement
    • Patient safety in health and care
    • Patient Safety Learning
    • Professionalising patient safety
    • Research, data and insight
    • Miscellaneous

Categories

  • Commissioning, service provision and innovation in health and care
    • Commissioning and funding patient safety
    • Health records and plans
    • Innovation programmes in health and care
    • Climate change/sustainability
  • Coronavirus (COVID-19)
    • Blogs
    • Data, research and statistics
    • Frontline insights during the pandemic
    • Good practice and useful resources
    • Guidance
    • Mental health
    • Exit strategies
    • Patient recovery
    • Questions around Government governance
  • Culture
    • Bullying and fear
    • Good practice
    • Occupational health and safety
    • Safety culture programmes
    • Second victim
    • Speak Up Guardians
    • Staff safety
    • Whistle blowing
  • Digital health and care service provision
    • Artificial Intelligence
    • Apps for health and care
    • Teleservices
    • Other health and care software
    • Digital health regulatory bodies/standards/guidance
  • Improving patient safety
    • Clinical governance and audits
    • Design for safety
    • Disasters averted/near misses
    • Equipment and facilities
    • Error traps
    • Health inequalities
    • Human factors (improving human performance in care delivery)
    • Improving systems of care
    • Implementation of improvements
    • International development and humanitarian
    • Patient Safety Alerts
    • Safety stories
    • Stories from the front line
    • Transformative Simulation
    • Workforce and resources
  • Investigations, risk management and legal issues
    • Investigations and complaints
    • Risk management and legal issues
  • Leadership for patient safety
    • Business case for patient safety
    • Boards
    • Clinical leadership
    • Exec teams
    • Inquiries
    • International reports
    • National/Governmental
    • Patient Safety Commissioner
    • Quality and safety reports
    • Techniques
    • Other
  • Organisations linked to patient safety (UK and beyond)
    • Government and ALB direction and guidance
    • International patient safety
    • Regulators and their regulations
  • Patient engagement
    • Consent and privacy
    • Harmed care patient pathways/post-incident pathways
    • How to engage for patient safety
    • Keeping patients safe
    • Patient-centred care
    • Patient Safety Partners
    • Patient stories
  • Patient safety in health and care
    • Care settings
    • Conditions
    • Diagnosis
    • High risk areas
    • Learning disabilities
    • Medication
    • Mental health
    • Men's health
    • Patient management
    • Social care
    • Transitions of care
    • Women's health
  • Patient Safety Learning
    • Patient Safety Learning documents
    • Patient Safety Standards
    • 2-minute Tuesdays
    • Patient Safety Learning Annual Conference 2019
    • Patient Safety Learning Annual Conference 2018
    • Patient Safety Learning Awards 2019
    • Patient Safety Learning Interviews
    • Patient Safety Learning webinars
  • Professionalising patient safety
    • Accreditation for patient safety
    • Competency framework
    • Medical students
    • Patient safety standards
    • Training & education
  • Research, data and insight
  • Miscellaneous

News

  • News

Find results in...

Find results that contain...


Date Created

  • Start
    End

Last updated

  • Start
    End

Filter by number of...

Joined

  • Start

    End


Group


First name


Last name


Country


About me


Organisation


Role

Found 58 results
  1. News Article
    Updated safety advice has been issued to strengthen warnings about potential psychiatric and sexual dysfunction linked to finasteride and to provide precautionary advice on dutasteride. Following an additional detailed review of the evidence, including the outcome of a European regulatory review, the MHRA has published a new Drug Safety Update and is updating product information for medicines containing finasteride and dutasteride to provide clearer guidance for healthcare professionals and patients. Finasteride is used to treat male pattern hair loss at a dose of 1mg, and benign prostatic hyperplasia at a dose of 5mg. Dutasteride (0.5mg) is used to treat benign prostatic hyperplasia. The updates include: strengthened warnings in the product information for finasteride 1mg for androgenetic alopecia to clarify that sexual dysfunction may contribute to mood disorders, and that sexual dysfunction has also been reported with and without mood alterations. a precautionary warning added to the product information for dutasteride to note that mood alterations have been reported with a medicine in the same class, finasteride. Existing UK patient alert cards for finasteride, introduced in 2024, remain in place. These cards highlight the risks of sexual dysfunction, depression and suicidal thoughts and advise patients on what action to take if side effects occur. Read full story Source: MHRA, 11 May 2026
  2. News Article
    Xanax, a drug used to treat anxiety disorders, has been placed under a nationwide recall in the USA Viatris, the maker of Xanax, recalled the medication last month because of “failed dissolution specifications,” according to a recent notice from the Food and Drug Administration. This means the pill may not break down in the body and release the drug at the right speed. If the medication doesn’t dissolve correctly, it could reduce its effectiveness. Last week, the FDA classified the recall as Class II, meaning the affected pills could cause “temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote,” according to the agency. A Viatris spokesperson told The Independent, “Patient safety and the quality of our medicines are of the utmost importance to Viatris. The voluntary recall of Xanax XR in the U.S. is specific to one lot of one strength (3mg) of the brand product only, and no other batches of the Xanax XR brand product, or its generics, are impacted.” Viatris said patients don’t need to take any action in connection with the recall and that wholesalers and pharmacies have been provided with instructions on how to return the affected Xanax. The drug maker said they have not received any reports of adverse reactions from the recalled product as of Wednesday. Read full story Source: The Independent, 16 April 2026
  3. News Article
    In a letter to healthcare professionals, drugs manufacturer Pfizer is to warn of serious and fatal adverse reactions following inadvertent administration of tranexamic acid instead of local anaesthetics. The letter, seen by The Pharmaceutical Journal and dated 30 April 2026, says: “Serious, including fatal, adverse reactions have been reported after inadvertent intrathecal administration [of tranexamic acid] due to mix-ups, mostly with injectable local anaesthetics.” Pfizer said it was sending the letter on behalf of marketing authorisation holders and in agreement with the Medicines and Healthcare products Regulatory Agency (MHRA). Tranexamic acid is an antifibrinolytic, used in the prevention and treatment of haemorrhages. “Intrathecal, epidural, intraventricular and intracerebral use of tranexamic acid solution for injection is contraindicated,” the letter added. “Cases of medication errors have been identified, including cases reported in the EU, where tranexamic acid injection was inadvertently administered intrathecally or epidurally. “Most of these cases involved mix-ups of vials or ampoules resulting in erroneous administration of tranexamic acid instead of the intended injectable local anaesthetic (e.g. bupivacaine, levobupivacaine, prilocaine).” It has added that, when administered intrathecally, serious patient harms had been reported, including prolonged hospitalisation and death, while serious adverse reactions that were reported include severe back, gluteal and lower limb pain, myoclonus, generalised seizures and cardiac arrhythmias. “Extreme caution should be taken when storing, handling and administering IV formulations of tranexamic acid to ensure the correct route of administration. This includes clearly labelling syringes containing tranexamic acid for IV use only and storing tranexamic acid injectables separately from injectable local anaesthetics,” it added. Read full story Source: The Pharmaceutical Journal, 14 April 2026
  4. News Article
    Taking acetaminophen – known in the US by the brand name Tylenol – during pregnancy has no effect on later autism diagnoses, according to a sweeping new study from Denmark published on Monday. The Trump administration has targeted Tylenol use in pregnancy as a major cause of autism in children, which appears to have led to a drop in pregnant people taking the pain reliever. Health officials announced in September 2025 that the US Food and Drug Administration (FDA) would initiate a label change for acetaminophen, warning of a potential link to autism. Trump cautioned several times against taking the pain reliever during pregnancy. “If you’re pregnant, don’t take Tylenol,” Trump said at a press conference at the time. “Don’t take Tylenol. Don’t have your baby take Tylenol.” He said the medication was “not good” and taking Tylenol during pregnancy was associated with “a very increased risk of autism”. Through Denmark’s robust national healthcare system, researchers were able to track more than 1.5 million children ‌born between 1997 and 2022 in the national health registry, including 31,098 children who were exposed to Tylenol in utero. Autism was diagnosed in 1.8% of children who were exposed to Tylenol and 3% of those who weren’t, according to the study, which was published in Jama Pediatrics. A similar 2024 study in Sweden found a marginal link that disappeared after taking siblings into account, suggesting that autism is strongly genetic, which has already been demonstrated in other studies. Tylenol is safe to take during pregnancy and can play a key role in relieving pain and bringing down fevers. Yet after the September announcement, Tylenol orders for pregnant women in emergency rooms dropped by 16% in the initial study period, according to a Lancet study published last month. Health officials’ “words are affecting behavior”, said Jeremy Faust, a co-author of that Lancet study, an emergency physician at Mass General Brigham and a health services researcher at Harvard Medical School. Read full story Source: The Guardian, 13 April 2026
  5. Content Article
    French actor / theatre director and hernia mesh advocate Arnaud Dennis is in an assisted dying clinic in Belgium. In this powerful interview the 42 year old speaks about how he is awaiting approval for euthanasia after devastating complications from a hernia mesh that destroyed his life. In this final public appeal, he denounces the major health scandal of mesh, giving his last thoughts to the hundreds of implant victims he has represented in France and warns of systemic medical and institutional failures – as well as the conflicts of interests /payments from industry to surgeons, which continue to help fuel the lucrative mesh machine.
  6. News Article
    Researchers at King’s College London have analysed coroners’ reports from across England, Wales and Northern Ireland to identify safety concerns linked to deaths involving fentanyl patches. Fentanyl is a highly potent and fast-acting synthetic opioid used to treat severe pain and is available in several forms, including injections, nasal sprays and skin patches. The study, which is published in the British Journal of Clinical Pharmacology, examined deaths associated with transdermal fentanyl patches between 1997 and 2024. While fentanyl can be an effective treatment for pain, it has also been linked to increasing numbers of drug-related deaths worldwide. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) has issued several safety warnings about the risk of accidental exposure to fentanyl patches and the importance of safe disposal. To better understand the risks, the researchers conducted a systematic case series linking two national sources of coronial data, the National Programme on Substance Use Mortality (NPSUM,) and the Preventable Deaths Tracker, which collects coroners’ Prevention of Future Deaths (PFD) reports. By linking these datasets, the team created the first comprehensive overview of fentanyl patch-related deaths reported by coroners. The analysis identified 99 deaths involving fentanyl patches between 1997 and 2024. Coroners reported 77 safety events linked to these deaths, with the most common issues relating to adherence and usage (34%), administration errors (32%) and prescribing practices (6%). The study also highlights differences in how deaths are reported across the two datasets, suggesting that important safety information from coroners may not always be systematically captured or monitored. As part of the project, the team also developed a live online dashboard that tracks Prevention of Future Deaths reports involving fentanyl patches in real time. The researchers hope this tool will support regulators, policymakers and healthcare professionals in monitoring safety concerns and improving prescribing practices. Read full story Source: Kings College London, 18 March 2026
  7. News Article
    Millions of Americans use injectable drugs like Novo Nordisk’s Ozempic and Wegovy to help them lose weight - knowing there are possible side effects such as nausea, vomiting and diarrhea. Now, the U.S. Food and Drug Administration has written a letter alleging that the Danish drugmaker failed to report adverse effects in patients who took semaglutide drugs, including death. The 5 March letter cited three deaths in unidentified patients, including one patient who died by suicide, and Director of the Office of Scientific Investigations Dr. David Burrow wrote that Novo Nordisk had failed to failed to report “serious and unexpected” adverse drug experiences within the FDA’s required time frame. “Based on your written procedure, your staff or contractor cancelled or rejected serious and unexpected adverse drug experiences that were required to be reported within 15 calendar days because they documented these events as being unrelated to the product,” Burrow said. However, the FDA stopped short in deciding whether any of the adverse effects were directly linked to the drug. The findings were based on an inspection of a New Jersey facility last year that Burrow said “revealed serious violations” of reporting requirements. Since then, Novo Nordisk had taken corrective and preventive actions that officials claimed were “inadequate” because the pharmaceutical giant “did not provide sufficient details to determine whether [Novo Nordisk’s] actions will effectively prevent similar violations in the future.” Read full story Source: The Independent, 12 March 2026
  8. Content Article
    This case study is one in a set of patient safety ‘how we acted on patient safety issues you recorded’ case studies which show the direct action taken in response to patient safety events recorded by organisations, staff and the public, and how their actions support the NHS to protect patients from harm. The National Patient Safety Team identified a report of a patient who was prescribed a corticosteroid for a period of two years but did not have the necessary regular reviews or monitoring for side effects to check the ongoing appropriateness of this medication. Corticosteroids are synthetic analogues of hormones produced by the adrenal cortex and are widely used in the management of many conditions. People receiving long-term oral corticosteroids (more than 3 weeks duration) and those needing frequent courses (three or four per year) should receive regular monitoring as they are at risk of adverse effects. NHS England noted that there was limited information relating to monitoring requirements for corticosteroids in the British National Formulary (BNF) clinical resource. NHS England liaised with the editorial board of the BNF who added information to the drug monograph entries for designated corticosteroids (for example, Dexamethasone) outlining the patient parameters to be monitored before starting and during treatment.
  9. News Article
    The deaths of two people in Northern Ireland potentially linked to weight-loss injections have been reported to the government agency responsible for ensuring medicines are safe. The two cases are among more than 500 suspected adverse drug reaction reports submitted from Northern Ireland over the last two years related to GLP-1 medications. The drugs, prescribed under names such as Wegovy and Mounjaro, are widely used across the UK for weight management and to treat diabetes. The reports were made to the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA said a report of a suspected reaction "does not necessarily mean it has been caused by the medicine, only that the reporter had a suspicion it may have". "Underlying or concurrent illnesses may be responsible, or the events could be coincidental," it added. The data shows that the two deaths were of a man and a woman, one who was in their 40s and the other in their 60s, although it does not specify which age category applied to which person. Read full story Source: BBC News, 9 March 2026
  10. News Article
    UK law firms are considering legal action on behalf of women who developed brain tumours after using the contraceptive injection Depo-Provera. Depo-Provera is a high-dose synthetic progesterone, prescribed for contraception and other menstrual symptoms, administered via injection every three months. According to UN calculations, 74 million women worldwide and 3.1% of UK women aged 15-49 use injectable contraception. Multiple studies have shown that women who take Depo-Provera have a much higher relative risk of developing meningiomas, though the overall risk remains low. Not normally cancerous, these benign tumours can cause seizures, blindness, hearing loss, headaches and memory problems. Now several law firms are hoping to take legal action against Pfizer in the UK. Austen Hays told the Guardian it had some potential clients, Fletchers’ website is actively seeking clients and Leigh Day said it is in the early stages of considering the legal basis for any case. Chaya Hanoomanjee, a partner at Austen Hays, said: “We have been approached by at least 30 women who have developed meningiomas following prolonged use of Depo-Provera. “Their lives have been considerably impacted due to having brain tumours, with consequences such as loss of vision and, in one case, a woman having to terminate her pregnancy. The duty here lies with Pfizer to ensure a drug is safe and to update warnings and contraindications as soon as new risks become known. “We are looking into the legal merits of each case, with a view to bringing a claim in the UK.” Read full story Source: The Guardian, 11 February 2026
  11. Content Article
    On 14 November 2024, an investigation commenced into the death of Master Avery Jake Hall, who died in Sunderland on 13 November 2024 aged 4 days. The Investigation concluded at the end of the Inquest on 23rd January 2026.  The medical cause of death was confirmed as: Ia Hypoxia Ischaemia and diffuse alveolar damage  Ib Olygo/anhydramnios and foetal distress  Ic Premature rupture of membranes, small placenta with distal villous maldevelopment and low grade foetal vascular malperfusion. Avery Jake Hall died at Sunderland Royal Hospital on 13th November 2024 having developed global hypoxia and diffuse alveolar damage with hyaline membranes in the lung following his birth as his development in pregnancy had been compromised by reduced amniotic fluid leading to poor lung development and impairment of urine production by the kidneys. During pregnancy Avery’s mother had continued to take Candesartan which had previously been prescribed to her to treat migraines. She did not receive definitive advice from clinicians to stop taking it despite various opportunities to do so and this is a medication contraindicated in pregnancy due to risks including foetal renal failure and pulmonary hypoplasia. Matters of concern Avery’s mother suffered from migraines which were increasing in severity, so she sought advice from her GP when aged 21 years old. She was prescribed Candesartan 4mg by her GP shortly before her 22nd birthday. This was to be taken daily and was placed on a repeat prescription of 28 tablets. The dose was increased to 8mg after 3 months and following a referral, the treatment was endorsed by a Consultant Neurologist at a consultation 4 months after the initial prescription. The evidence revealed that no advice was provided as to the risks of this medication should she be considering having a child. Following a positive pregnancy test in April 2024, Avery’s mother sought advice from her GP about which of her prescribed medications were safe to use during pregnancy. During the telephone consultation with her GP on 11 April 2024 she was given specific advice to avoid using 3 of 6 prescriptions. However the evidence highlighted that Avery’s mother was given only generic advice that it was best to avoid all medication during pregnancy but was not given specific advice to stop using Candesartan, and the risk of continuing to take this medication in pregnancy was not identified during this consultation. Although Avery’s mother had a number of attendances with clinicians throughout her antenatal care, the evidence revealed that she was given no additional advice regarding the safety of her medication and, whilst she was advised to seek advice from her GP as the prescriber, she did not feel it was necessary to do so having already had such a consultation in April 2024. Avery’s mother continued to suffer from migraines during her pregnancy and was unaware of the risk posed by taking Candesartan in pregnancy due to a lack of clear and definitive advice about the risk. I am concerned that she was able to resume taking Candesartan approximately 14 days after her initial GP consultation as the medication remained on a repeat prescription which she was able to continue to request during her pregnancy, and each request was approved without a detailed review. The last repeat prescription being approved only 12 days prior to Avery’s birth. The coroner's concern is that despite advice from the GP that it was best to stop all medication during pregnancy, Candesartan remained as a repeat prescription and, in addition to that, there were no warnings placed on the system which would have alerted the clinician approving the request for the repeat prescription that the patient was pregnant thus necessitating a review.
  12. News Article
    Patients on weight-loss jabs and diabetes injections should be aware there is a small risk of developing severe acute pancreatitis, the UK medicines regulator has said. About 1.6 million adults in England, Wales and Scotland used GLP-1 medication, such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), between early 2024 and early 2025 to lose weight, according to recent research. Patient information leaflets for Wegovy, Ozempic and Mounjaro list pancreatitis as an “uncommon” reaction, affecting about one in 100 patients. Acute pancreatitis occurs when the pancreas, a gland located behind the stomach that aids in digestion, becomes suddenly inflamed. Symptoms include severe pain in the abdomen, nausea and fever, with patients often ending up in hospital. While acknowledging that pancreatitis is rare, on Thursday the Medicines and Healthcare products Regulatory Agency (MHRA) updated its guidance, after an increase in reports of acute pancreatitis to the agency’s yellow card scheme, which monitors any adverse reactions to medications and medical devices in the UK. Read full story Source: The Guardian, 29 January 2026
  13. Content Article
    The MHRA has reviewed the warnings regarding addiction, dependence, withdrawal, and tolerance for gabapentin, pregabalin, benzodiazepines, and z-drugs. The findings (detailed in the Public Assessment Report) were that it was necessary to strengthen these warnings in the product information and on packaging to better inform healthcare professionals and patients of these known risks. Advice for healthcare professionals: Gabapentinoids (pregabalin and gabapentin), benzodiazepines and z-drugs are three classes of medicines used to treat a variety of conditions such as neuropathic pain, anxiety and insomnia. Specialist use of these medications for conditions such as epilepsy, or sedation during medical procedures are not included in this review. All three classes of medications are known to pose risks of addiction, dependency, withdrawal and tolerance. The Summary of Product Characteristics, Patient Information Leaflets and Outer Packaging of these medicines will have strengthened warnings to better communicate the risks of addiction, dependency, withdrawal and tolerance to healthcare professionals and patients. Updates are in progress and will be rolled out over the coming months. Prior to starting treatment with these medicines, a discussion should be held with patients to put in place a strategy for reducing or ending treatment. By doing this the risk of addiction, dependence, and drug withdrawal syndrome is reduced. NICE guideline, NG215, has resources that include visual summaries which are available to support these discussions. The Agency has also developed additional patient resources for benzodiazepines, gabapentinoids and z-drugs which highlight key messages concerning these risks and should be made available to patients when these medications are prescribed. Addiction and dependence are related but have distinct presentations. Healthcare professionals are reminded of the importance of using non-judgmental language when discussing these terms. Patients may find that treatment is less effective with chronic use and express a need to increase the dose to obtain the same level of symptom control as initially experienced. This could be a sign that the patient is developing tolerance. The risks of developing tolerance should be explained to the patient. Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to reduce symptoms of withdrawal. Tapering from a high dose may take weeks or months. Patients should be informed of this when the medication is first prescribed and should be encouraged to speak to their healthcare professional or prescriber before stopping their medicine. See NICE guideline NG 215 for identifying and managing withdrawal symptoms. Provide regular support especially to individuals at increased risk of drug withdrawal syndrome, such as those with current or past history of substance use disorder (including alcohol misuse) or mental health disorder. Addiction, dependence, withdrawal or tolerance in response to these medications can be reported via the Yellow Card scheme Advice for healthcare professionals to provide to patients: As these medicines carry risks of addiction, dependence and withdrawal reactions, before starting treatment with these medicines, your healthcare professional should explain how long you might need to take them for, and how to stop safely. This helps reduce the risk of addiction, dependence, and drug withdrawal syndrome. Anyone can become physically dependent on these medicines, meaning that their body gets used to it, and this can cause them to have withdrawal symptoms if the medicine is suddenly stopped, or the dose is reduced. Drug addiction can feel like a strong desire to take the medicine, and difficulties in controlling medicine use (for example feeling like you want to take more or use the medicine when you shouldn’t). Addiction and dependence are related but they are not the same, being physically dependent on a medicine does not necessarily mean you are addicted to it. Drug tolerance can mean no longer feeling like the medicine is working well, or feeling that a higher dose is required to achieve the same symptom relief as before. If you want to stop taking your medicine there are additional resources to help you. Never stop taking your medication without asking a healthcare professional first. If you are taking this medicine for epilepsy, you should keep taking it for as long as your doctor says it’s needed. If you find that your treatment is not working as well, you should speak to your healthcare professional about possible alternative treatment options, and you should never take more of your medicine than you have been prescribed. When it is time to stop your medication, your healthcare professional will tell you how to gradually reduce the amount of medicine you are taking over time (known as dose tapering). This is very important to reduce the risk of drug withdrawal syndrome. Dose tapering can sometimes take weeks or months. Mild symptoms may still occur, but you should contact your healthcare professional if the withdrawal symptoms become intolerable.
  14. Content Article
    Unsafe medication practices and medication-related harm are one of the leading causes of avoidable harm in health and care. This year’s #MedSafetyWeek focuses on the theme “we can all help make medicines safer”. We have collated patient interviews and blogs shared on the hub that raise awareness of medication adverse reactions, and resources on how you can report a problem. 1 MHRA: The Yellow Card Scheme The Yellow Card Scheme helps the Medicines and Healthcare products Regulatory Agency (MHRA) monitor the safety of all healthcare products in the UK to ensure they are acceptably safe for patients and those who use them. On the Yellow Card Scheme website you can report a suspected incident or problem. 2 The question that will save lives: Interview with Katinka Blackford Newman, founder of Antidepressant Risks Antidepressant medications are taken by millions of people globally. A small percentage of people who take them will experience rare but dangerous adverse reactions. In this interview, Katinka Blackford Newman tells us about her personal experience of antidepressant-induced psychosis and how this led her to campaign for increased awareness about side effects. She highlights a widespread lack of education and awareness about the risks associated with antidepressants and outlines why she is asking suicide prevention charities to ask callers one simple question about their medication. 3 Patient Safety Spotlight interview with Marie Lyon, chair of the Association for Children Damaged by Hormone Pregnancy Tests In this interview, Marie Lyon talks about her campaign for justice for families affected by hormone pregnancy tests, why she is passionate about reforming medicines regulation and the important role patient campaigners play in improving patient safety. 4 USA: FDA Adverse Event Reporting System (FAERS) public dashboard FAERS is the U.S. Food and Drug Administration (FDA) primary database for collecting and analysing adverse event reports, serious medication errors, and product quality complaints for prescription drugs and therapeutic biologics, containing reports submitted by healthcare professionals, consumers, and manufacturers. 5 Recognising adverse events and using the yellow card system Despite the role of the MHRA’s Yellow Card reporting system in pharmacovigilance in the UK, understanding and uptake of the scheme remains limited. East London NHS Foundation Trust share how they designed a survey to explore healthcare professionals’ awareness, usage and perceptions of the Yellow Card Scheme for reporting adverse drug reactions. 6 Post-SSRI Sexual Dysfunction: After 30 years, why is the health system still failing to recognise this life-limiting adverse effect? Post-SSRI Sexual Dysfunction (PSSD) is a long-term adverse effect of Selective Serotonin Reuptake Inhibitors (SSRIs), a type of antidepressant medication. In this opinion piece, Harriet Vogt, Patient Safety Partner at NHS Sussex Integrated Care Board, outlines the need for recognition and research into PSSD to allow patients to make truly informed choices when considering SSRIs. She looks at the impact PSSD has on the sexual and emotional lives of thousands of people and highlights a new research study analysing the obstacles to quantifying its incidence and prevalence. Harriet argues that while the health system is beginning to recognise the value of placing patients at the heart of efforts to improve safety, this focus on listening is rarely given to individual patients who express concern about the impact of their medication or treatment. 7 MHRA: Reporting a possible side effect to a medicine – a guide for Children and Young People The MHRA has produced a guide to download and share to help children and young people learn why it's important to report possible side effects of medication. 8 Sodium Valproate: The Fetal Valproate Syndrome Tragedy In this article, Sharon Hartles, member of the Open University’s Harm and Evidence Research Collaborative, reflects upon the use of Sodium Valporate, marketed as Epilim, to treat patients at risk of epilepsy and the subsequent harms in fetal development and birth defects that arose from its use. ‘ 9 Interview with Charlet Crichton, founder of UKCVFamily UKCVFamily was set up in November 2021 to support patients in the UK who have had an adverse reaction to a Covid-19 vaccination. The group provides help and advocacy as well as raising awareness amongst healthcare professionals, the media and the Government. In this video, founder of UKCVFamily Charlet Crichton talks to us about the side effects she experienced after having the AstraZeneca Covid vaccine. She outlines why she established the group and describes the support it offers to patients. She outlines some of the issues people face when trying to access diagnosis and treatment, and discusses the limitations of the MHRA's Yellow Card scheme in collecting data about adverse reactions. She also describes how healthcare professionals can support people with adverse reactions by taking their concerns seriously and investigating symptoms thoroughly. Share your stories Have you had an adverse reaction to medication? What do you think of the Yellow Card reporting system? Share your thoughts and experiences with us on the hub. You can comment below (you will need to be signed in first; sign up is free and easy) or email us at [email protected].
  15. News Article
    The Medicines and Healthcare products Regulatory Agency (MHRA) is urging the public to help keep medicines, medical devices, vaccines and blood products safe by reporting any side effects, device incidents and suspected fake medical products, as part of #MedSafetyWeek (3–9 November). The global campaign is marking its tenth year, bringing together more than 130 regulators and health organisations across 117 countries with one shared message: everyone has a role to play in medicine safety. Reporting matters more than ever With more people using medicines and medical devices than ever before – from weight loss treatments to wearable monitors – safety reporting is a key part of protecting public health. An estimated 2.5 million people in the UK are now using weight loss medicines, many bought online and delivered by post. Thousands use glucose sensors or blood-pressure monitors in the comfort of their own homes. As medicines and medical devices play a bigger role in daily life, including to prevent illness rather than treat it, public reporting of safety concerns is more important than ever. Professor Anthony Harnden, MHRA Chair, said: “Healthcare has changed significantly over the past decade, alongside advances in science and technology. Medicines and medical devices are part of everyday life for millions of people, and many are accessed in new ways, including online. “If you experience a side effect, notice a device isn’t working properly, or suspect a fake medical product, please tell us via the MHRA’s Yellow Card scheme. Your report could protect others – and it only takes minutes.” Read full story Source: MHRA, 3 November 2025
  16. Content Article
    In this blog, Sling the Mesh discusses the powerful and thoughtful letter published in the journal Hernia by Nicholas T.H. Farr, titled “Absence of evidence is not evidence of absence – Rethinking NHS England’s inguinal hernia surgery decision aid.” Farr’s letter challenges a key statement in NHS England’s decision support tool (DST) for inguinal hernia surgery, which claims that “none” of the patients experienced allergic or autoimmune reactions to hernia mesh. Farr rightly points out that such a definitive claim is not supported by the available evidence – and more importantly, that it misrepresents the uncertainty that still exists in the scientific literature. “Saying there is no evidence of an event is not the same as stating the event did not occur.” This distinction is vital. It goes to the heart of informed consent and patient trust. Farr’s letter highlights that while manufacturers of mesh products often include warnings about potential allergic reactions in their Instructions for Use (IFUs), the DST fails to reflect this nuance. Instead, it presents a level of certainty that the evidence simply doesn’t justify. Further reading on the hub from Nicholas Farr Medical device safety: effective testing is key
  17. Content Article
    Adverse event reporting is critical for advancing patient safety within healthcare systems. A significant factor in enhancing reporting rates is establishing a 'just culture'; a framework that emphasises accountability and learning over punitive measures. While just culture significantly enhances adverse event reporting, its successful implementation requires robust commitment at all organisational levels. Reporting adverse events is essential for ensuring patient safety and fostering a culture of continuous improvement in healthcare. Adverse events, defined as unintended injuries or complications arising from healthcare management, offer crucial insights into systemic weaknesses that, if addressed, can prevent future harm. However, underreporting such events remains a significant challenge, often driven by fear of punitive actions, reputational damage or legal repercussions. To address these concerns and promote a robust reporting culture, healthcare organisations must adopt a just culture by implementing standardised frameworks for evaluating errors and establishing robust reporting systems. Transparency in handling reported incidents is critical for building trust among healthcare professionals. Understanding just culture Just culture represents a shift from a blame-oriented approach to one that balances accountability with a focus on systemic improvement. Originating in high-risk industries such as aviation, the concept emphasises that errors result from flawed processes rather than individual negligence. In a just culture, individuals are held accountable for their actions within a fair and transparent system that prioritises learning and improvement. Central to the philosophy of just culture is the idea of psychological safety. When healthcare professionals feel confident reporting errors will not lead to unjust punishment, they are more likely to disclose incidents. This openness enables organisations to identify trends, address root causes and implement preventive measures. Moreover, just culture recognises the distinction between human errors, at-risk behaviours, and reckless conduct, advocating for tailored responses that align with the nature of the behaviour. Barriers to adverse event reporting Despite its potential, the implementation of just culture faces several obstacles. A predominant challenge is the deeply ingrained blame culture within many healthcare organisations. Historical reliance on punitive measures has created an environment where professionals fear repercussions, discouraging transparency. Additionally, managerial inconsistency in addressing errors often undermines trust in the system. For instance, discrepancies in how similar incidents are handled can create perceptions of unfairness, further discouraging reporting. Another barrier is the lack of understanding and awareness of just culture principles among healthcare staff. Without proper training and education, employees may misinterpret the approach as being lenient or as failing to hold individuals accountable. Legal and regulatory pressures also pose challenges, as concerns about litigation can deter organisations from fully embracing non-punitive reporting frameworks. Strategies for implementing just culture Implementing a just culture in healthcare requires a multifaceted approach that addresses organisational, managerial and individual factors. Leadership commitment is paramount; leaders must model just cultural behaviours, demonstrate accountability and prioritise safety over blame. Developing clear policies and guidelines for error classification and response is equally important as it ensures consistency and fairness in how incidents are addressed. Education and training programmes are vital in promoting awareness and understanding of just culture principles. These programmes should emphasise the distinction between human errors, at-risk behaviours and reckless conduct, providing staff with the tools to respond appropriately. Role-playing scenarios, workshops and case studies can help reinforce these concepts and demonstrate their practical application. The integration of non-punitive reporting systems is another critical component. Such systems should be designed to facilitate easy and confidential reporting, with mechanisms to protect the anonymity of reporters when appropriate. Feedback loops are essential for ensuring that staff are informed about the outcomes of reported incidents, which can reinforce the value of reporting and build trust in the system. Measuring the impact of just culture Assessing the effectiveness of just culture initiatives requires the development of standardised metrics and evaluation tools. Key performance indicators may include reporting rates, staff perceptions of psychological safety and the frequency of systemic improvements resulting from reported incidents. Periodic surveys and interviews can provide valuable insights into staff attitudes and identify areas for improvement. Case studies from organisations that have successfully implemented just culture can also serve as benchmarks for best practices. For instance, hospitals that report significant increases in adverse event reporting rates following the adoption of just culture principles often attribute their success to strong leadership, comprehensive training, and consistent application of policies. Sustaining cultural change Sustaining a just culture requires ongoing commitment and adaptability. Organisations must regularly evaluate their policies and practices to ensure alignment with just culture principles. Staff feedback should be actively sought and incorporated into decision-making processes, fostering a sense of ownership and engagement. Continuous education and training are essential for reinforcing just culture behaviours and addressing emerging challenges. Additionally, leadership succession planning should prioritise candidates who are committed to upholding just culture principles, ensuring continuity in organisational values. Conclusion Adverse event reporting is a fundamental component of patient safety, and the principles of just culture provide a robust framework for enhancing reporting rates and fostering systemic improvements. By balancing accountability with a focus on learning and improvement, just culture creates an environment where healthcare professionals feel empowered to report incidents without fear of retribution. Leadership commitment, staff education and integrating non-punitive reporting systems are critical for overcoming barriers and sustaining cultural change. A just culture represents a paradigm shift in addressing adverse events, emphasising systemic improvement over individual blame. Its successful adoption has the potential to transform healthcare organisations, making them safer and more resilient. Future research should focus on developing standardized metrics to evaluate just culture initiatives and exploring their applicability across diverse healthcare settings.
  18. News Article
    While millions of Americans have turned to popular weight loss drugs to shed pounds in recent years, taking them isn’t without some risks. Now, research led by the scientists at the Centers for Disease Control and Prevention has found that tens of thousands of Americans have ended up in the emergency room after taking semaglutide: the active ingredient in GLP-1 drugs, including drugmaker Novo Nordisk’s Ozempic and Wegovy. The findings may be an indicator that more patient education is necessary when it comes to taking the drugs. “We found that it’s very infrequent that semaglutide leads to very serious adverse events that would land a patient in the hospital, but that they do occur,” Dr. Pieter Cohen, an associate professor of medicine at Harvard Medical School, told Health. Using national surveillance data collected at dozens of hospitals, they estimated that semaglutide had been a contributing factor in nearly 25,000 emergency room visits from 2022 to 2023. More than 82 percent of those visits occurred in 2023, and the reason was usually gastrointestinal complications. Patients experienced nausea, vomiting, stomach pain, and diarrhoea. Some people also came into emergency rooms with allergic reactions and hypoglycemia, which is also known as low blood sugar. A handful of patients were diagnosed with pancreatitis and just four were diagnosed with biliary disease, which impacts the gallbladder. Read full story Source: The Independent, 1 May 2025
  19. News Article
    Patients prescribed drugs for movement disorders - including restless leg syndrome (RLS) - say doctors did not warn them about serious side effects that led them to seek out risky sexual behaviour. Twenty women have told the BBC that the drugs - given to them for RLS, which causes an irresistible urge to move - ruined their lives. A report by drugs firm GSK - seen by the BBC - shows it learned in 2003 of a link between the medicines, known as dopamine agonist drugs, and what it described as "deviant" sexual behaviour. It cited a case of a man who had sexually assaulted a child while taking the drug for Parkinson's. While there is no explicit reference to this side effect in patient leaflets, the UK medicines regulator told us there was a general warning, external about increased libido and harmful behaviour. GSK says a risk of "altered" sexual interest is also referred to in the leaflets. Some of the women who described being drawn to risky sexual behaviour told us they had no idea of what was causing it. Others said they felt compelled to gamble or shop with no history of such activities. One accumulated debts of more than £150,000. In a statement, GSK told the BBC Ropinirole had been prescribed for more than 17 million treatments and undergone "extensive clinical trials". It added the drug had proven to be effective and had a "well-characterised safety profile". "As with all medicines, [it] has potential side effects and these are clearly stated in the prescribing information," it said. The UK's Medicines and Healthcare products Regulatory Agency (MHRA), said that while a specific reference to "deviant" sexual behaviour is not included in warnings, such impulses vary and a general warning about activities which may be harmful is included. It also said that it is important for healthcare professionals to explain the possible risk to patients and not all experience these types of side effects. Read full story Source: BBC News, 11 March 2025
  20. News Article
    Scores of people with multiple sclerosis (MS) have suffered debilitating side-effects after being put on to a cheaper new drug as part of an NHS drive to save money. About 170 MS patients at Charing Cross hospital in London have had complications, including a relapse of their illness, after being switched from Tysabri to a different drug called Tyruko, made by the pharmaceutical company Sandoz. In a handful of cases, the people affected developed such serious symptoms that they had to be taken to hospital for treatment. Patients have told doctors about side-effects including an inability to use their legs, other mobility problems, fatigue, pain and sudden weight gain. It is unclear how widespread the adverse reactions to Tyruko are. NHS England said the problem has only been seen at the London hospital. However, one of the patients there claimed to know of people with MS being treated at 15 other hospitals in England who have experienced similar setbacks to their health after being moved on to Tyruko after sometimes years taking Tysabri. Problems have arisen since NHS England began moving patients across the country with very active relapsing remitting MS from Tysabri on to Tyruko, a “biosimilar” drug, last April. A biosimilar is a version of a drug that has fallen out of patent, allowing other pharmaceutical firms to legally make a medicine that is as safe and effective as the original but on average 72% cheaper. The side-effects from Tyruko are causing so much concern within the health service that NHS England is in discussion with the Department of Health and Social Care (DHSC) and the Medicines and Healthcare products Regulatory Agency (MHRA) about what to do. A spokesperson for Sandoz said: “Patient safety is our first priority. We are seeking to understand the situation at Imperial healthcare NHS trust, which appears to contrast with the experience of patients at other UK hospitals. We believe it’s premature to draw conclusions at this point. We continue to work with the NHS and regulatory authorities to resolve this.” Read full story Source: The Guardian, 24 May 2025
  21. News Article
    "Who will look after our children when we're no longer here? At the moment that's nobody." Catherine Cox, from Keyworth in Nottinghamshire, was one of thousands of women who took the epilepsy drug, sodium valproate, while pregnant, something which is now advised against. Her son Matthew, now 23, was born with a range of conditions, including autism, ADHD, epilepsy and several learning disabilities. At the age of 18 months, he was diagnosed with foetal valproate syndrome, indicating the medication his mother took was the cause of his problems. Mrs Cox has been campaigning for compensation ever since. It is thought thousands of children in the UK have been left with disabilities caused by valproate since the 1970s. Before undergoing fertility treatment, Mrs Cox was advised it was "fine" to continue taking valproate. "To then find out that the medication that you have taken in good faith has caused the problems your child will carry for the whole of their life is an awful thing," she told the BBC. Mrs Cox told the BBC she had grown weary of a lack of action from successive governments. In February 2024, a report by the Patient Safety Commissioner, Henrietta Hughes, said there was a "clear" and "urgent" need to compensate those harmed by valproate, both financially and otherwise. More than a year has since passed, and the government is still working on a response. Mrs Cox said: "We have pulled various governments over time kicking and screaming to this point where they have acknowledged that the difficulties for up to 20,000 children were caused by this drug. "As we go on, what we need is something to make up for their loss of potential." Read full story Source: BBC News, 17 February 2025 Related reading on the hub: A year on from The Hughes Report: Urgent action needed on redress Primodos, mesh and sodium valproate: Recommendations and the UK Government’s response (Sharon Hartles)
  22. News Article
    The parents of Thomas Kingston have warned about the side effects of antidepressants after he took his own life. Mr Kingston died from a head injury in February last year at his parents' home in the Cotswolds. A gun was found near his body. The 45-year-old had stopped taking his medication, which had been prescribed by a GP at the Royal Mews Surgery in the days leading up to his death. His parents, Martin and Jill Kingston, are now calling for a change in how patients are prescribed selective serotonin reuptake inhibitors (SSRI) - a widely used type of antidepressant. Martin Kingston told BBC Radio 4's Today programme he believes both the patient and the people close to them should be told more explicitly about the potential side effects of the medication, including what can happen if they stop taking it. The couple want patients to sign a document confirming they've been told about the difficulties of going on and coming off the medication. This could include the patient being told that "it's an extreme case, but it could lead to suicide", Mrs Kingston says. "We'd really like to see that a person, a spouse, a partner, a parent, a close friend, somebody, was going to walk with them through it. Maybe they should be at that signing time." Recording a narrative conclusion at an inquest into his death in December, Katy Skerrett, senior coroner for Gloucestershire, said Thomas Kingston had taken his own life. "The evidence of his wife, family and business partner all supports his lack of suicidal intent," she said at the inquest. "He was suffering adverse effects of medication he had recently been prescribed." In a prevention of future deaths report, made in January, Ms Skerrett said action must be taken over the risk to patients prescribed SSRIs. She questioned whether there was adequate communication of the risks associated with such medication. Read full story Source: BBC News, 4 January 2025 Related reading on the hub: The question that will save lives: Interview with Katinka Blackford Newman, founder of Antidepressant Risks Long-lasting sexual dysfunction after taking antidepressants: Lack of recognition harmful to patients Post-SSRI Sexual Dysfunction: After 30 years, why is the health system still failing to recognise this life-limiting adverse effect?
  23. Content Article
    Understanding the effects of Covid-19 infection and vaccination during pregnancy can help inform clinical guidance and overcome concerns about vaccine safety. This study examined relationships between Covid-19 infection during pregnancy, Covid-19 vaccination during pregnancy and early child developmental concerns in children aged 13–15 months in Scotland. The study found that Covid-19 infections during pregnancy do not appear to be linked to early childhood developmental concerns and vaccinations during pregnancy appear to be safe from the perspective of early childhood developmental concerns. As some developmental concerns do not become apparent until children are older than 13–15 months, the authors recommended that future research continue to monitor outcomes as children grow and develop. You will need to sign up for a free Lancet account to view this article.
  24. Content Article
    Mr Thomas Henry Robin Kingston was a 45 year old man who was visiting his parents in Kemble Gloucestershire for the weekend. He had recently been experiencing anxiety, but had not expressed any suicidal ideation. On Sunday 25 February 2024 after lunch he began to unload his car, and prepared to return to London. Between approximately 1700-1800 hours he removed a shotgun from his vehicle which he had recently borrowed from his father for a shoot. He then accessed an annex attached to his parent’s property. Within a locked bathroom he self inflicted a gun shot to the head, and sustained injuries incompatible with life. He was subsequently found by his father. He was pronounced deceased at 1854 hours by attending police, who confirmed there were no suspicious circumstances surrounding his death. Intent remains unclear as the deceased was suffering from adverse effects of medications he had recently been prescribed. The medical cause of death was 1A Traumatic wound to head.                  Matters of Concern Whether there is adequate communication of the risks of suicide associated with the selective serotonin reuptake inhibitor (SSRI) medications, and Whether the current guidance to persist with SSRI medication or switch to an alternative SSRI medication is appropriate when no benefit has been achieved and/ or especially when any adverse side effects are being experienced.
  25. Content Article
    This was a debate in the House of Commons on the 16 January 2025 discussing the performance of the Medicines and Healthcare products Regulatory Agency (MHRA), the body responsible for the regulation of medicines and medical devices in the UK. The motion debated focused on the MHRA’s performance in relation to patient safety matters, including: the agency’s work on the hormone pregnancy tests, the Yellow Card System and safety monitoring, funding and the influence of the pharmaceutical industry and the implementation of recommendations made by the Independent Medicines and Medical Devices Safety review.
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.